Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
|Articles|October 13, 2011
Poll: What treatment option do you use with women who miscarry and have fibroids?
Author(s)OBGYN.net Staff
In a recent study of women with repeated miscarriages and fibroids, researchers found that removing them significantly increased the live birth rate. This increase was noted with both fibroids that distorted the uterine cavity as well as those that did not.
Advertisement
In a recent
Advertisement
Related to this article
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Risa Kagan, MD, on why the menopause transition is a critical window for bone loss and how women can preserve bone mass.
This FAQ summarizes a Special Report discussion on testosterone pellet therapy in women and advice for hesitant prescribers.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Risa Kagan, MD, on bone health across a woman's lifetime
2
FAQ: Where do testosterone pellets stand for women?
3
FAQ: What does the evidence show about testosterone in women?
4
HRSA opens $1 million funding to update women's preventive guidelines
5